Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $147 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico reiterates an Outperform rating on Neurocrine Biosciences (NBIX) and maintains a $147 price target.
April 17, 2024 | 5:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico reaffirmed an Outperform rating on Neurocrine Biosciences, with a price target of $147.
The reaffirmation of an Outperform rating and a high price target by a reputable analyst like Laura Chico suggests a strong bullish sentiment towards NBIX. This could positively influence investor perception and potentially drive the stock price up in the short term, especially if the market aligns with Wedbush's analysis.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100